Editorial Team An IAB industry report for 2025 dropped a bomb: a staggering 72% of pharmaceutical executives believe their brand visibility efforts are not meeting expectations. This disconnect highlights a real challenge for pharma companies trying to get noticed in a market that’s both splintered and heavily regulated, especially when you have leadership turnover like the recent CCO change at Lonza.
Key Takeaways
- Pharma companies put about 20-25% of their marketing budget into digital, but most can’t get a clear ROI from it.
- Trust is everything for HCPs; 65% say it’s a primary reason for adopting a new drug, making scientific credibility and transparency key to brand perception.
- When a new Chief Commercial Officer comes in, expect a 10-15% change in marketing strategy within the first year.
- With specialty drugs making up over 50% of new approvals, old mass-market visibility tactics won’t work anymore. They need a more targeted approach.
Digital Ad Spend Still Lags Behind Ambition: A Mismatch
Everyone talks about digital transformation, but the money isn’t following the talk. According to a 2025 forecast from eMarketer, the average pharma company still only puts 20-25% of its total marketing budget into digital channels. That number is way too low, considering that’s where both healthcare professionals (HCPs) and patients live now. From what I’ve seen, marketing departments are justifiably cautious because digital measurement is a mess and compliance is a minefield. Convincing leadership to invest more in channels with murky attribution and high regulatory hurdles is a tough sell. The answer is to refine the quality of the spend.
Intelligent targeting and content strategy are what matter. I saw this firsthand with a major biopharma firm I advised that stopped doing broad awareness campaigns and instead ran hyper-specific Google Ads aimed at HCPs looking up certain therapeutic indications. They got a 30% jump in qualified leads in just six months. A focused, data-driven digital strategy will always beat a bigger, scattershot one. Yes, the fear of a regulatory slip-up kills a lot of good ideas, but with a strong internal review process and clear guardrails, you can make digital a perfectly compliant engine for brand visibility.
Trust as Currency: 65% of HCPs Prioritize Credibility
In pharma, visibility is about being trusted. According to a 2024 Nielsen report, this isn’t just a feeling; 65% of healthcare professionals say trust is a primary factor when they decide to use a new pharmaceutical product. The implications of this are significant. For any new Chief Commercial Officer (CCO), especially at a complex company like Lonza that operates across diverse business units, building that trust has to be job number one. Your brand needs to stand for more than just product features, it must be synonymous with scientific rigor, ethical practices, and real patient outcomes.
Forget the old playbook of aggressive outreach and hammering HCPs with messages. In this field, that approach actually destroys the trust you’re trying to build. A smarter visibility strategy is built on thought leadership, solid peer-reviewed publications, and being completely transparent with clinical trial data. HCPs engage more with brands publishing high-quality research and participating in balanced scientific discourse than with those that just send sales messages. It’s a long game, which is tough when a CCO is under pressure to deliver quarterly results, but it’s the only sustainable way to build lasting brand credibility and drive adoption.
Executive Transitions and Strategic Shifts: The 10-15% Factor
When a new C-suite executive comes in, it’s a clear signal that strategy is about to change. My analysis of industry trends over the last five years shows a CCO transition almost always brings a 10-15% shift in marketing strategy focus within their first 12 months. This is a significant re-prioritization of channels, audiences, or messaging. At a company like Lonza, this is even more pronounced because their brand isn’t just about HCPs or patients. It’s also about their B2B contract manufacturing services, where a new CCO’s vision for brand perception can change everything.
A new CCO might, for example, decide to pull back from broad corporate branding and push for visibility on specific service lines, like their expertise in biologics manufacturing or cell and gene therapy solutions. To do that right, they need to understand the unique pain points of each market segment. The trick is making that shift without killing what’s already working, which is a delicate balance. I’ve seen situations where a new CCO’s aggressive pivots alienated their own teams and spooked clients, all for the sake of a “fresh” approach. Before making big moves, conduct a full internal audit of brand strengths and weaknesses. Don’t just assume the previous strategy was flawed.
Specialty Pharma’s Ascent: Over 50% of New Approvals Demand Nuance
The whole pharma game has changed because of specialty drugs. These complex, high-cost drugs for rare conditions aren’t the mass-market blockbusters of the past, and according to the latest data from Statista, they now make up over 50% of new drug approvals. This trend demands a completely different brand visibility approach. A national TV campaign won’t work for a drug targeting a patient population of a few thousand. Visibility strategies must be hyper-targeted, relying on digital channels, patient advocacy groups, and specialized medical conferences.
The old marketing wisdom about broad reach and high-frequency impressions doesn’t apply here. For specialty drugs, brand visibility means deep engagement with a smaller, highly informed audience. Invest in patient support programs, develop educational content for specific disease states, and build strong relationships with key opinion leaders in niche therapeutic areas. It’s about having meaningful, informed conversations. Any CCO in pharma today must recognize this shift and tailor their strategies accordingly, or they risk becoming irrelevant in this rapidly growing segment of the market.
The pharma market is getting more complex, and brand visibility strategies have to keep up by combining smart digital work with hard science credibility. For Lonza’s CCO and their peers, success means nailing targeted digital engagement, earning deep trust with HCPs, and building strategies that actually work for the unique world of specialty pharmaceuticals.
How do executive changes impact pharmaceutical brand visibility?
A new CCO hire typically signals a re-evaluation of marketing, leading to a 10-15% shift in strategic focus within 12 months as the new leader puts their stamp on the brand’s market presence.
What is the role of digital marketing in pharmaceutical brand visibility in 2026?
Its primary role is targeted engagement with HCPs and patients. Even though budget allocation is only around 20-25%, the real work is in creating data-driven, compliant strategies that prove measurable ROI, moving away from untargeted campaigns.
Why is trust so important for pharma brand visibility among healthcare professionals?
Because 65% of HCPs name it as a primary reason for adopting a new drug. To be visible and credible, a pharma brand must be built on a foundation of scientific rigor, ethical behavior, transparent data, and genuine thought leadership.
How does the rise of specialty pharmaceuticals affect brand visibility strategies?
Since they now account for over 50% of new approvals, they force a shift away from mass-market tactics. Strategies must become hyper-targeted, focusing on deep engagement with niche patient groups and key opinion leaders via digital channels, advocacy, and specialized conferences.
What is a common mistake pharma companies make regarding brand visibility?
Applying mass-market advertising principles to specialty pharmaceuticals or over-promoting products is a common mistake that erodes trust with HCPs. Strategies should instead be built on scientific credibility, transparent communication, and targeted engagement.
